ID   1363-mel
AC   CVCL_8042
SY   1363-MEL; 1363 mel; 1363
DR   Cosmic; 876704
DR   Wikidata; Q54581660
RX   PubMed=10048982;
RX   PubMed=19581576;
CC   From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*01,02 (PubMed=10048982).
CC   Derived from site: Metastatic; Not specified.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_WY45 ! 1363-EBV
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 14
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; PMCID=PMC2072935;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=19581576; DOI=10.1073/pnas.0903852106; PMCID=PMC2715484;
RA   Depontieu F.R., Qian J., Zarling A.L., McMiller T.L., Salay T.M.,
RA   Norris A., English A.M., Shabanowitz J., Engelhard V.H., Hunt D.F.,
RA   Topalian S.L.;
RT   "Identification of tumor-associated, MHC class II-restricted
RT   phosphopeptides as targets for immunotherapy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:12073-12078(2009).
//